Compare TNL & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | PBLS |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2006 | 2026 |
| Metric | TNL | PBLS |
|---|---|---|
| Price | $80.33 | $30.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $88.38 | $41.00 |
| AVG Volume (30 Days) | 815.6K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.66 | N/A |
| Revenue | ★ $4,021,000,000.00 | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $5.21 | $300.17 |
| P/E Ratio | $16.87 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $60.34 | $22.66 |
| 52 Week High | $81.00 | $42.49 |
| Indicator | TNL | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 76.29 | 52.61 |
| Support Level | $71.82 | $26.42 |
| Resistance Level | N/A | $33.65 |
| Average True Range (ATR) | 2.51 | 2.17 |
| MACD | 1.08 | 0.64 |
| Stochastic Oscillator | 98.97 | 80.19 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.